洛拉替尼对比克唑替尼一线治疗亚洲晚期ALK阳性非小细胞肺癌:CROWN研究五年结局
CROWN研究亚洲亚组五年随访事后分析显示,洛拉替尼组(59例)中位无进展生存期未达到,克唑替尼组(61例)为9.2个月,风险比0.22;两组五年无进展生存率分别为63%和7%。基线脑转移患者颅内客观缓解率洛拉替尼组69%、克唑替尼组6%,安全性与总体人群一致。
要点
- 亚洲亚组中洛拉替尼组中位无进展生存期未达到,克唑替尼组为9.2个月,风险比0.22。
- 两组五年无进展生存率分别为63%和7%,客观缓解率分别为81%和59%。
- 基线脑转移患者颅内客观缓解率洛拉替尼组69%、克唑替尼组6%,安全性与总体人群一致。
核心结论
- 五年随访后,CROWN研究亚洲亚组中洛拉替尼的疗效和安全性继续与总体人群一致,洛拉替尼组无进展生存期仍未达到。
研究设计与样本
- CROWN研究(NCT03052608)为3期试验,亚洲患者按1:1随机接受洛拉替尼100 mg每日一次(59例)或克唑替尼250 mg每日两次(61例)。
- 本分析为事后分析,报告更新后的研究者评估疗效、安全性和生物标志物分析结果。
主要发现
- 洛拉替尼组中位随访62.4个月、克唑替尼组55.1个月,中位无进展生存期分别为未达到(95%CI 64.3至未达到)和9.2个月(95%CI 7.2至12.7),风险比0.22(95%CI 0.13至0.37)。
- 五年无进展生存率洛拉替尼组63%(95%CI 49至74)、克唑替尼组7%(95%CI 2至17)。
- 客观缓解率洛拉替尼组81%(95%CI 69至90)、克唑替尼组59%(95%CI 46至71)。
- 基线脑转移患者颅内客观缓解率洛拉替尼组69%(95%CI 39至91)、克唑替尼组6%(95%CI 小于1至30)。
- 至颅内进展中位时间洛拉替尼组未达到(95%CI 未达到至未达到)、克唑替尼组14.6个月(95%CI 9.2至27.4),风险比0.01(95%CI 小于0.01至0.11)。
关键数值与推荐
- 洛拉替尼组中位无进展生存期未达到(95%CI 64.3至未达到),克唑替尼组9.2个月(95%CI 7.2至12.7),风险比0.22(95%CI 0.13至0.37)。
- 五年无进展生存率洛拉替尼组63%(95%CI 49至74),克唑替尼组7%(95%CI 2至17)。
- 客观缓解率洛拉替尼组81%(95%CI 69至90),克唑替尼组59%(95%CI 46至71)。
- 基线脑转移患者颅内客观缓解率洛拉替尼组69%(95%CI 39至91),克唑替尼组6%(95%CI 小于1至30)。
- 至颅内进展中位时间洛拉替尼组未达到(95%CI 未达到至未达到),克唑替尼组14.6个月(95%CI 9.2至27.4),风险比0.01(95%CI 小于0.01至0.11)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lorlatinib, a third-generation anaplastic lymphoma kinase inhibitor, reported significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patients with previously untreated advanced anaplastic lymphoma kinase-positive NSCLC. Efficacy was similar in the Asian subgroup. We present an updated subgroup analysis in Asian patients after five years of follow-up. METHODS: Patients were randomly (1:1) assigned to receive lorlatinib 100 mg once daily (n = 59) or crizotinib 250 mg twice daily (n = 61). This post hoc analysis presents updated investigator-assessed efficacy outcomes, safety, and biomarker analyses. RESULTS: After a median follow-up of 62.4 months for lorlatinib and 55.1 months for crizotinib, median PFS was not reached (NR, 95% confidence interval [CI]: 64.3‒NR) and 9.2 months (95% CI: 7.2‒12.7), respectively (hazard ratio [HR] = 0.22, 95% CI: 0.13‒0.37); the five-year PFS was 63% (95% CI: 49-74) and 7% (95% CI: 2-17). The objective response rate was 81% (95% CI: 69-90) with lorlatinib and 59% (95% CI: 46‒71) with crizotinib. In patients with baseline brain metastases, the intracranial objective response rate was 69% (95% CI: 39‒91) with lorlatinib and 6% (95% CI: <1‒30) with crizotinib. The median time to intracranial progression was NR (95% CI: NR‒NR) and 14.6 months (95% CI: 9.2‒27.4), respectively (HR = 0.01, 95% CI: <0.01‒0.11). Safety profiles were consistent with the entire population. CONCLUSIONS: After five years of follow-up, lorlatinib efficacy and safety in the Asian subgroup of CROWN continue to be consistent with those in the overall population, with PFS remaining unreached with lorlatinib. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03052608.
引用
- Wu YL, Kim HR, Soo RA, et al. First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. J Thorac Oncol. 2025. PMID: 40024442. doi:10.1016/j.jtho.2025.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。